Search research articles
Contact Us
Filters
Showing results (11-20 of 21) with videos related to
Page
of 3
Sort By:
BMC Musculoskeletal Disorders
|
March 23, 2013
The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis
Laura C Coates, Nuria Navarro-Coy, Sarah R Brown, et al.
BMC Musculoskeletal Disorders
|
February 8, 2012
Pressure and pain in systemic sclerosis/scleroderma--an evaluation of a simple intervention (PISCES): randomised controlled trial protocol
Begonya Alcacer-Pitarch, Maya H Buch, Janine Gray, et al.
BMC Oral Health
|
September 4, 2012
IMPROVDENT: improving dentures for patient benefit. A crossover randomised clinical trial comparing impression materials for complete dentures
Janine C Gray, Nuria Navarro-Coy, Sue H Pavitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
Andy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Lancet (London, England)
|
December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Haematologica
|
November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
Gareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood
|
June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
Gareth J Morgan, Faith E Davies, Walter M Gregory, et al.
The Lancet. Oncology
|
July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J Morgan, J Anthony Child, Walter M Gregory, et al.
BMC Musculoskeletal Disorders
|
January 21, 2014
The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome
Sarah Brown, Nuria Navarro Coy, Costantino Pitzalis, et al.
British Journal of Haematology
|
March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results
Graham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Page
of 3
Search research articles
Search
Showing results (11-20 of 21) with videos related to
Sort By:
Page
of 3
BMC Musculoskeletal Disorders
|
March 23, 2013
The TICOPA protocol (TIght COntrol of Psoriatic Arthritis): a randomised controlled trial to compare intensive management versus standard care in early psoriatic arthritis
Laura C Coates, Nuria Navarro-Coy, Sarah R Brown, et al.
BMC Musculoskeletal Disorders
|
February 8, 2012
Pressure and pain in systemic sclerosis/scleroderma--an evaluation of a simple intervention (PISCES): randomised controlled trial protocol
Begonya Alcacer-Pitarch, Maya H Buch, Janine Gray, et al.
BMC Oral Health
|
September 4, 2012
IMPROVDENT: improving dentures for patient benefit. A crossover randomised clinical trial comparing impression materials for complete dentures
Janine C Gray, Nuria Navarro-Coy, Sue H Pavitt, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
June 5, 2013
Minimal residual disease assessed by multiparameter flow cytometry in multiple myeloma: impact on outcome in the Medical Research Council Myeloma IX Study
Andy C Rawstron, J Anthony Child, Ruth M de Tute, et al.
Lancet (London, England)
|
December 7, 2010
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
Gareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Haematologica
|
November 8, 2011
Cyclophosphamide, thalidomide, and dexamethasone as induction therapy for newly diagnosed multiple myeloma patients destined for autologous stem-cell transplantation: MRC Myeloma IX randomized trial results
Gareth J Morgan, Faith E Davies, Walter M Gregory, et al.
Blood
|
June 10, 2011
Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation
Gareth J Morgan, Faith E Davies, Walter M Gregory, et al.
The Lancet. Oncology
|
July 21, 2011
Effects of zoledronic acid versus clodronic acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC Myeloma IX): secondary outcomes from a randomised controlled trial
Gareth J Morgan, J Anthony Child, Walter M Gregory, et al.
BMC Musculoskeletal Disorders
|
January 21, 2014
The TRACTISS protocol: a randomised double blind placebo controlled clinical trial of anti-B-cell therapy in patients with primary Sjögren's Syndrome
Sarah Brown, Nuria Navarro Coy, Costantino Pitzalis, et al.
British Journal of Haematology
|
March 29, 2014
Osteonecrosis of the jaw and renal safety in patients with newly diagnosed multiple myeloma: Medical Research Council Myeloma IX Study results
Graham H Jackson, Gareth J Morgan, Faith E Davies, et al.
Page
of 3